An investigation on behalf of investors of Spark Therapeutics, Inc. (NASDAQ: ONCE) in connection with the proposed takeover was announced and NASDAQ: ONCE stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 03/06/2019 -- An investigation on behalf of investors, who currently hold shares of Spark Therapeutics, Inc. (NASDAQ: ONCE), was announced concerning whether the takeover of Spark Therapeutics, Inc. is unfair to NASDAQ: ONCE stockholders.
Investors who purchased shares of Spark Therapeutics, Inc. (NASDAQ: ONCE) and currently hold any of those NASDAQ: ONCE shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain officers and directors of Spark Therapeutics, Inc. breached their fiduciary duties owed to NASDAQ: ONCE investors in connection with the proposed acquisition.
Philadelphia, PA based Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. On February 25, 2019, Spark Therapeutics (NASDAQ: ONCE) announced that it has entered into a merger agreement for Roche to fully acquire Spark Therapeutics at a price of $114.50 per share in an all-cash transaction.
However, given that at least one analyst has set the high target price NASDAQ: ONCE shares at $115.00 per share, the investigation concerns whether the offer is unfair to NASDAQ: ONCE stockholders. More specifically, the investigation concerns whether the Spark Therapeutics Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Shares of Spark Therapeutics, Inc. (NASDAQ: ONCE) closed on March 5, 2019, at $113.90 per share.
Those who are current investors in Spark Therapeutics, Inc. (NASDAQ: ONCE) shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels